| abstract |
The invention relates to a compound of formula IA, in which ring A may be substituted with one or more R, designated R and R; G is N; Q is C; X is CH; Y is O; equal to 1; equal to 1; R is R, R, R and R, each independently selected from the group consisting of H, halo, CN and C1-6 alkyl; R is imidazolyl, oxazolyl or triazolyl; R 1 is pyrimidinyl or —C (═O) OR, wherein pyrimidinyl may be substituted with C 1-6 alkyl; R is C1-6alkyl; R is hydrogen and R is hydrogen, halo or CN; possessing modulating activity against the GPR119 receptor conjugated to the G-protein, as well as its enantiomers, diastereomers and pharmaceutically acceptable salts. The invention also provides a method for modulating the activity of a GPR119-coupled G protein receptor, comprising administering to the mammal a therapeutically effective amount of at least one compound of formula IA and, optionally, an additional therapeutic agent, as well as a pharmaceutical composition comprising a compound of formula IA. |